论文部分内容阅读
目的:系统评价醒脑静注射液辅助治疗小儿热性惊厥的有效性和安全性。方法:计算机检索1990-2013年在PubMed、CNKI、VIP、CBM、万方等数据库公开发表的醒脑静注射液辅助治疗小儿热性惊厥的随机对照研究。评价纳入文献的质量和提取有效数据后,应用RevMan 5.2统计学软件进行Meta分析。结果:共纳入12篇文献,均为中文文献,其中Jadad评分3分的1篇,2分的2篇,其余均为1分。Meta分析结果显示,试验组与对照组的临床有效性[RR=1.25,95%CI(1.17,1.33),P<0.01]、退热时间[MD=-1.16,95%CI(-1.43,-0.90),P<0.01]、意识恢复正常时间[MD=-2.88,95%CI(-3.07,-2.68),P<0.01]、住院时间[MD=-1.24,95%CI(-1.91,-0.58),P<0.01]、转化为复杂性热性惊厥例数[RR=0.30,95%CI(0.12,0.72),P<0.01]、复发例数[RR=0.21,95%CI(0.09,0.47),P<0.01]均优于对照组,且安全性较好。结论:醒脑静注射液能显著提高小儿热性惊厥的临床治疗有效性,改善患儿的临床症状和体征,其安全性较好,但对远期预后的影响尚需进一步的临床研究。
Objective: To evaluate the effectiveness and safety of Xingnaojing injection in the treatment of pediatric febrile seizures. METHODS: Randomized controlled clinical trials of Xingnaojing injection in adjuvant treatment of children with febrile seizures from 1990 to 2013 in PubMed, CNKI, VIP, CBM and Wanfang databases were performed. After evaluating the quality of the included literature and extracting valid data, Meta-analysis was performed using the RevMan 5.2 statistical software. Results: A total of 12 articles were included, all of which were Chinese. Among them, 1 was rated 3 for Jadad, 2 for 2, and 1 for the rest. The results of Meta analysis showed that the clinical effectiveness of the experimental group and the control group [RR = 1.25,95% CI (1.17,1.33), P <0.01], antipyretic time [MD = -1.16,95% CI -1.43, 0.90), P <0.01], and the recovery time of normal consciousness [MD = -2.88,95% CI -3.07, -2.68, P <0.01]. The length of hospital stay [MD = -1.24,95% CI -1.91, (RR = 0.30, 95% CI (0.12, 0.72), P <0.01], and the number of recurrence [RR = 0.21,95% CI (0.09, 0.47), P <0.01] were better than the control group, and the safety is better. Conclusion: Xingnaojing injection can significantly improve the clinical efficacy of pediatric febrile seizures and improve the clinical symptoms and signs of children, its safety is good, but the long-term prognosis needs further clinical study.